2012 Current Cancer Dedicated to bringing the latest news and information on cancer diagnosis, treatment and prevention.

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved Avastin (bevacizumab) in combination with standard chemotherapy (carboplatin and paclitaxel) as a front-line (first-line following surgery) treatment for women with advanced ovarian cancer. Ovarian cancer is the most deadly of the gynaecological cancers, with approximately 220,000 women diagnosed and 140,000 women ...

First targeted biological therapy to show survival benefit in stomach cancer Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved Herceptin (trastuzumab) in combination with chemotherapy for use in patients with HER2-positive metastatic stomach (gastric) cancer. The approval is based on the impressive results from the international ToGA trial, which ...